To investigate the association of CD24 and CD44 expression with recurrence-free survival, we analyzed cohorts of prostate cancer patients36 and confirmed that high expression levels of both markers (CD24 and CD44) were associated with favourable recurrence-free survival (Fig. 5). Here, CD24 is linked to prostate cancer.